301 related articles for article (PubMed ID: 21617218)
1. Efficient down-regulation of CDK4 by novel lipid nanoparticle-mediated siRNA delivery.
Wang X; Yu B; Wu Y; Lee RJ; Lee LJ
Anticancer Res; 2011 May; 31(5):1619-26. PubMed ID: 21617218
[TBL] [Abstract][Full Text] [Related]
2. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
[TBL] [Abstract][Full Text] [Related]
3. Cellular uptake mechanism and knockdown activity of siRNA-loaded biodegradable DEAPA-PVA-g-PLGA nanoparticles.
Benfer M; Kissel T
Eur J Pharm Biopharm; 2012 Feb; 80(2):247-56. PubMed ID: 22085653
[TBL] [Abstract][Full Text] [Related]
4. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
Yang XZ; Dou S; Sun TM; Mao CQ; Wang HX; Wang J
J Control Release; 2011 Dec; 156(2):203-11. PubMed ID: 21839126
[TBL] [Abstract][Full Text] [Related]
5. Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth.
Kang MR; Yang G; Place RF; Charisse K; Epstein-Barash H; Manoharan M; Li LC
Cancer Res; 2012 Oct; 72(19):5069-79. PubMed ID: 22869584
[TBL] [Abstract][Full Text] [Related]
6. Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression.
Grillo M; Bott MJ; Khandke N; McGinnis JP; Miranda M; Meyyappan M; Rosfjord EC; Rabindran SK
Breast Cancer Res Treat; 2006 Jan; 95(2):185-94. PubMed ID: 16319987
[TBL] [Abstract][Full Text] [Related]
7. Functional gene silencing mediated by chitosan/siRNA nanocomplexes.
Ji AM; Su D; Che O; Li WS; Sun L; Zhang ZY; Yang B; Xu F
Nanotechnology; 2009 Oct; 20(40):405103. PubMed ID: 19752491
[TBL] [Abstract][Full Text] [Related]
8. A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy.
Mao CQ; Du JZ; Sun TM; Yao YD; Zhang PZ; Song EW; Wang J
Biomaterials; 2011 Apr; 32(11):3124-33. PubMed ID: 21277018
[TBL] [Abstract][Full Text] [Related]
9. Efficacious gene silencing in serum and significant apoptotic activity induction by survivin downregulation mediated by new cationic gemini tocopheryl lipids.
Kumar K; Maiti B; Kondaiah P; Bhattacharya S
Mol Pharm; 2015 Feb; 12(2):351-61. PubMed ID: 25438085
[TBL] [Abstract][Full Text] [Related]
10. PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest.
Datta NS; Chen C; Berry JE; McCauley LK
J Bone Miner Res; 2005 Jun; 20(6):1051-64. PubMed ID: 15883646
[TBL] [Abstract][Full Text] [Related]
11. Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells.
Kim CJ; Nishi K; Isono T; Okuyama Y; Tambe Y; Okada Y; Inoue H
Mol Carcinog; 2009 Oct; 48(10):953-64. PubMed ID: 19415719
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor binding protein-3 induces G1 cell cycle arrest with inhibition of cyclin-dependent kinase 2 and 4 in MCF-7 human breast cancer cells.
Kim HS; Lee WJ; Lee SW; Chae HW; Kim DH; Oh Y
Horm Metab Res; 2010 Mar; 42(3):165-72. PubMed ID: 19960406
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of PAI-1 expression in breast cancer carcinoma cells by siRNA at nanomolar range.
Meryet-Figuières M; Resina S; Lavigne C; Barlovatz-Meimon G; Lebleu B; Thierry AR
Biochimie; 2007 Oct; 89(10):1228-33. PubMed ID: 17509745
[TBL] [Abstract][Full Text] [Related]
14. [RNAi-mediated gene silencing of livin synergistic with epirubicin enhance apoptosis of human breast cancer cells].
Liang CY; Ma P; Liu XL
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(24):1703-6. PubMed ID: 19024543
[TBL] [Abstract][Full Text] [Related]
15. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
Kim HK; Davaa E; Myung CS; Park JS
Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
[TBL] [Abstract][Full Text] [Related]
16. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
18. Antibody-modified lipid nanoparticles for selective delivery of siRNA to tumors expressing membrane-anchored form of HB-EGF.
Okamoto A; Asai T; Kato H; Ando H; Minamino T; Mekada E; Oku N
Biochem Biophys Res Commun; 2014 Jul; 449(4):460-5. PubMed ID: 24853808
[TBL] [Abstract][Full Text] [Related]
19. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
[TBL] [Abstract][Full Text] [Related]
20. The efficiency of CD40 down regulation by siRNA and antisense ODN: comparison of lipofectamine and FuGENE6.
Ebadi P; Karimi MH; Pourfathollah AA; Saheb Ghadam Lotfi A; Soheili ZS; Samiee S; Hajati S; Nadali F; Geramizadeh B; Moazzeni SM
Iran J Immunol; 2009 Mar; 6(1):1-11. PubMed ID: 19293472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
